RT Journal Article
SR Electronic
T1 Modeling the relative influence of socio-demographic variables on post-acute COVID-19 quality of life: an application to settings in Europe, Asia, Africa, and South America
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.02.21.24303099
DO 10.1101/2024.02.21.24303099
A1 Menkir, Tigist F.
A1 Citarella, Barbara Wanjiru
A1 Sigfrid, Louise
A1 Doshi, Yash
A1 Reyes, Luis Felipe
A1 Calvache, Jose A.
A1 Kildal, Anders Benjamin
A1 Nygaard, Anders B.
A1 Holter, Jan Cato
A1 Panda, Prasan Kumar
A1 Jassat, Waasila
A1 Merson, Laura
A1 Donnelly, Christl A.
A1 Santillana, Mauricio
A1 Buckee, Caroline
A1 Verguet, Stéphane
A1 Hejazi, Nima S.
YR 2024
UL http://medrxiv.org/content/early/2024/02/23/2024.02.21.24303099.abstract
AB Long-term COVID-19 complications are a globally pervasive threat, but their plausible social drivers are often not prioritized. Here, we use data from a multinational consortium to quantify the relative contributions of social and clinical factors to differences in quality of life among participants experiencing long COVID and measure the extent to which social variables’ impacts can be attributed to clinical intermediates, across diverse contexts. In addition to age, neuropsychological and rheumatological comorbidities, educational attainment, employment status, and female sex were identified as important predictors of long COVID-associated quality of life days (long COVID QALDs). Furthermore, a great majority of their impacts on long COVID QALDs could not be tied to key long COVID-predicting comorbidities, such as asthma, diabetes, hypertension, psychological disorder, and obesity. In Norway, 90% (95% CI: 77%, 100%) of the effect of belonging to the highest versus lowest educational attainment quintile was not attributed to intermediate comorbidity impacts. The same was true for 86% (73%, 100%) of the protective effects of full-time employment versus all other employment status categories (excluding retirement) in the UK and 74% (46%,100%) of the protective effects of full-time employment versus all other employment status categories in a cohort of four middle-income countries (MIC). Of the effects of female sex on long COVID QALDs in Norway, UK, and the MIC cohort, 77% (46%,100%), 73% (52%, 94%), and 84% (62%, 100%) were unexplained by the clinical mediators, respectively. Our findings highlight that socio-economic proxies and sex may be as predictive of long COVID QALDs as commonly emphasized comorbidities and that broader structural determinants likely drive their impacts. Importantly, we outline a multi-method, adaptable causal machine learning approach for evaluating the isolated contributions of social disparities to long COVID quality of life experiences.Competing Interest StatementMS has received institutional research funds from the Johnson and Johnson foundation and from Janssen global public health. MS also received institutional research funding from Pfizer. Funding StatementTFM acknowledges support from NIH Training Grant 2T32AI007535. LFR was funded by Universidad de La Sabana (MED-309-2021). MS has been funded (in part) by contracts 200-2016-91779 and cooperative agreement CDC-RFA-FT-23-0069 with the Centers for Disease Control and Prevention (CDC). The findings, conclusions, and views expressed are those of the author(s) and do not necessarily represent the official position of the CDC. MS was also partially supported by the National Institute of General Medical Sciences of the National Institutes of Health under award number R01GM130668.This work was made possible by the UK Foreign, Commonwealth and Development Office and Wellcome [215091/Z/18/Z, 222410/Z/21/Z, 225288/Z/22/Z and 220757/Z/20/Z], the Bill & Melinda Gates Foundation [OPP1209135], the philanthropic support of the donors to the University of Oxford's COVID-19 Research Response Fund (0009109), grants from the National Institute for Health Research (NIHR award CO-CIN-01/DH_/Department of Health/United Kingdom), the Medical Research Council (MRC grant MC_PC_19059), and by the NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE), 29 (award 200907), NIHR HPRU in Respiratory Infections at Imperial College London with PHE (award 200927), Liverpool Experimental Cancer Medicine Centre (grant C18616/A25153), NIHR Biomedical Research Centre at Imperial College London (award ISBRC-1215-20013), and NIHR Clinical Research Network providing infrastructure support, the Comprehensive Local Research Networks (CLRNs) of which PJMO is an NIHR Senior Investigator (NIHR201385), Cambridge NIHR Biomedical Research Centre (award NIHR203312), the Research Council of Norway grant no 312780, and a philanthropic donation from Vivaldi Invest A/S owned by Jon Stephenson von Tetzchner to the Norwegian SARS-CoV-2 study, the South Eastern Norway Health Authority and the Research Council of Norway.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ISARIC-WHO Clinical Characterisation Protocol was approved by the World Health Organization Ethics Review Committee (Ref RPC571/RPC572 25APR13). Institutional Ethics Committee approval was additionally obtained by participating sites including the South Central Oxford C Research Ethics Committee in England (Ref 13/SC/0149), Leeds West Research Ethics Committee (Ref 20/YH/0225), and the Scotland A Research Ethics Committee (Ref 20/SS/0028) for the United Kingdom and the Human Research Ethics Committee (Medical) of the University of the Witwatersrand (Ref M2010108) for South Africa, representing the majority of the data. Other institutional and national approvals were obtained by participating sites as per local requirements. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that underpin this analysis are highly detailed clinical data on individuals hospitalised with COVID-19. Due to the sensitive nature of these data and the associated privacy concerns, they are available via a governed data access mechanism following review of a data access committee. Data can be requested via the IDDO COVID-19 Data Sharing Platform (http://www.iddo.org/covid-19). The Data Access Application, Terms of Access and details of the Data Access Committee are available on the website. Briefly, the requirements for access are a request from a qualified researcher working with a legal entity who have a health and/or research remit; a scientifically valid reason for data access which adheres to appropriate ethical principles.The full terms are at: https://www.iddo.org/document/covid-19-data-access-guidelines. A small subset of sites who contributed data to this analysis have not agreed to pooled data sharing as above. In the case of requiring access to these data, please contact the corresponding author in the first instance who will look to facilitate access. All code (with the exception of code used to process the individual datasets) is publicly available at: https://github.com/goshgondar2018/social_long_covid. https://github.com/goshgondar2018/social_long_covid